The level of ALT (U/L) was significantly higher in the ARDS-COVID-19 group [38.45 (22.93–73.38)] than in the non-ARDS-COVID-19 [29.45 (19–40.2)] and suspected non-COVID-19 [20 (12–31.75)] groups. The gene discussed is GPT; the disease is COVID-19.